Patent 11752158 was granted and assigned to EirGen Pharma on September, 2023 by the United States Patent and Trademark Office.
The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.